Member Exclusive News

The week in industry: CAD$10 Million awarded to develop novel cancer therapies

This week: bluebird bio gains first approval for their gene therapy ZYNTEGLO™, the first and only drug for episodic cluster headaches approved by US FDA and more companies join the Quantum Leap project to improve novel intracellular delivery technology.

Jun 06, 2019
0
0

Please sign in or register for FREE

No comments yet.